Monte Rosa Therapeutics, Inc. (GLUE)

USD 3.63

(-8.1%)

Market Cap (In USD)

223.28 Million

Revenue (In USD)

-

Net Income (In USD)

-135.35 Million

Avg. Volume

705.94 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.21-12.4
PE
-3.7
EPS
-0.98
Beta Value
1.3
ISIN
US61225M1027
CUSIP
61225M102
CIK
1826457
Shares
61509800.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Markus Warmuth M.D.
Employee Count
-
Website
https://www.monterosatx.com
Ipo Date
2021-06-24
Details
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.